Background: Patients with advanced lung adenocarcinomas expressing ALK rearrangements are highly responsive to crizotinib, a dual ALK/c-MET inhibitor. Immunohistochemistry (IHC) is an easy clinically and routinely applicable costeffective assay for ALK, c-MET and ROS1 protein expression for potential treatment with crizotinib. The purpose of this study was to evaluate the percentage and the pattern of ALK-rearranged cells, the variation in the native ALK copy number, as well as ALK, c-MET and ROS1 protein expression, and their significance on outcome of crizotinib-treated lung adenocarcinoma patients.
introduction
Anaplastic lymphoma kinase (ALK) gene rearrangements are detected in ∼5% of unselected lung adenocarcinomas [1] . This frequency increases to ∼29% in a subset of patients that were males, young, never/light smokers, patients with an advanced stage at presentation, in adenocarcinoma with solid architecture and signet-ring cell features, and without EGFR and KRAS gene mutations [2] . Crizotinib is an approved molecule for the treatment of advanced ALK-rearranged lung adenocarcinoma patients [3] . While crizotinib may rapidly induce tumor regression in certain patients, not all patients respond. Partial response to crizotinib was reported in non-small-cell lung cancer (NSCLC) patients with MET amplification in the absence of an ALK rearrangement [4, 5] . Moreover, chromosomal rearrangements involving the ROS1 receptor tyrosine kinase have also been recently described in NSCLC, while the latest results from phase I trials indicate that crizotinib is an effective therapy for advanced ROS1-positive NSCLC [6, 7] . In addition to the ratio of tumor cells expressing ALK rearrangements, the FISH assay provides biological information on the copy number per cell in both the native and rearranged ALK genes [8] .
Other ALK diagnostic techniques have been developed, including immunohistochemistry (IHC) for the detection of the chimeric ALK protein and reverse transcriptase-polymerase chain reaction (RT-PCR) analysis to search for the presence of abnormal fusion transcripts [9, 10] . Several studies showed that IHC is sensitive and specific for determination of ALK protein expression and is an accessible cost-effective and rapid alternative to the ALK FISH assay [11] [12] [13] [14] . Most importantly, some authors reported significant clinical improvement with crizotinib in patients with tumors that were designated as ALKnegative by FISH but were found to be ALK-positive by IHC, raising the possibility that the FISH assay may miss cases that could benefit from crizotinib [15, 16] .
In this study, we evaluated the ALK status using FISH and an automated standardized IHC assay in a prospective cohort of 176 lung adenocarcinomas 'double-negative' (wild-type EGFR and KRAS) giving emphasis to discordant cases on potential biological considerations such as the percentage and the pattern of ALK-rearranged cells, the variation in the native ALK copy number, and their significance to outcome with crizotinib. Additionally, we evaluated by IHC the baseline expression of the other crizotinib targets, c-MET and ROS1, in these cases.
materials and methods

patients
One hundred seventy-six formalin-fixed paraffin-embedded (FFPE) consecutive samples of advanced stage IIIb/IV lung adenocarcinomas that were tested for ALK status at the Laboratory of Clinical and Experimental Pathology (Pasteur Hospital, Nice, France) were investigated. Patients were surgically explored in the departments of Pneumology and Thoracic Surgery (Pasteur Hospital) between November 2012 and February 2014 (supplementary Material, available at Annals of Oncology online). A subset of the investigated patients received crizotinib treatment and had clinical data available on the outcome with crizotinib (n = 19). Patients received crizotinib treatment as standard care after EMA approval.
fluorescence in situ hybridization FISH analysis was carried out on 4-µm-thick FFPE tissue sections using the Abbott ALK break-apart probe (Vysis LSI ALK Dual Color; Abbott Molecular, Rungis, France), according to the manufacturer's technical instructions as previously described [12] (supplementary Material, available at Annals of Oncology online). To detect aneusomy in chromosome 2, FISH was carried out using the chromosome 2 enumeration probe (CEP2, Abbott), according to the manufacturer's technical instructions. All FISH slides with borderline positivity or discordant data between FISH and IHC were scanned for up to 12 different focal planes (z-stack) and enumerated with the automated PathScan imaging software (PATHSCAN® FISH, Excilone, Elancourt, France) without the knowledge of the FISH and the IHC data.
ALK, c-MET and ROS1 immunohistochemistry
All staining procedures were carried out on a Ventana BenchMark XT automated immunostainer (Ventana Medical Systems, Roche Group, Tucson, AZ) [3, 14, 17] (supplementary Material, available at Annals of Oncology online). After CC1 antigen retrieval, tissue sections were incubated with the primary antibody: anti-ALK rabbit monoclonal antibody (Clone D5F3, prediluted, Ventana), CONFIRM anti-total c-MET rabbit monoclonal antibody (Clone SP44, prediluted, Ventana) and anti-ROS1 rabbit monoclonal antibody (Clone D4D6, 1 : 100 dilution, Cell Signaling Technology, Danvers, MA). The OptiView DAB IHC Detection Kit (Ventana) and the OptiView Amplification Kit (Ventana) were used according to the manufacturer's recommendations. For the ROS1 immunostaining procedure, the XT UltraView DAB kit was used (Ventana), without amplification.
EML4-ALK reverse transcription-polymerase chain reaction RNA was extracted (Qiagen, Hilden, Germany) from the FFPE tissue sections and qualified using Agilent Bioanalyzer (Agilent, Massy-Palaiseau, France). Reverse transcription and PCR amplification (RT-PCR) was carried out using published primers and protocols [18] . Surprisingly, in these discordant cases, the initial FISH analysis revealed that these cases had more than 15% tumor nuclei with ALK rearrangements, but all were below 20% ALK positivity with a BA pattern of rearrangement. Thus, in the present study population, 19% of tumors were identified as ALK 'borderline'-positive cases. The second ALK FISH-automated analysis confirmed the ratio of ALK positivity between 15% and 20% in all but one case. Initially classified by FISH as positive by the two readers, expressing 17% percent of ALK-rearranged nuclei, this case was (13) 153 (87) 138 (78) 36 (20) 2 (2) 38 (22) 138 (78) 1 (1) 175 ( identified as negative (14%), below the threshold of 15% of cells for the automated FISH analysis. Moreover, all the cases did not contain the most frequent EML4-ALK fusion transcripts as revealed by RT-PCR analysis. FISH with CEP2 identified a low native ALK copy number in one case. We further analyzed the expression of c-MET and ROS1 in the five discordant ALK FISH 'borderline'-positive and ALK IHC-negative cases. Three of five tumors overexpressed c-MET (supplementary Figure S2 , available at Annals of Oncology online). None of the tumors expressed ROS1. Of note, the frequency of c-MET overexpression in the ALK-FISH-positive tumors was 23% and no ROS1 expression was found (Table 1) . Furthermore, two tumors considered negative for ALK on FISH, were classified as positive by the IHC assay. These tumors exhibited heterogeneous staining ranging from moderate/strong staining in 50%-60% of tumor cells to faint/no labeling in the remaining cells (Figure 2) . The automated FISH analysis revealed an ALK-BA pattern in 10% and 12% of tumor nuclei, respectively. In exchange, the CEP2 FISH analysis in the two discordant IHC-positive and FISH-negative cases revealed high levels of ALK polysomy with clusters or more than six isolated signals (mean copy number ratio, 3; range, 6-11; Figure 2 ). No c-MET or ROS1 expression was detected by IHC in the two tumors.
crizotinib response in ALK-FISH-rearranged patients
Preliminary data on the crizotinib response were collected from a subset of 19 patients (Table 2) . Among the 21 ALK-FISH-positive and IHC-positive patients, 14 were treated with crizotinib, a dual ALK/c-MET inhibitor. Seven had a documented complete response and two had a partial response. Of these patients three showed high c-MET expression (two with complete responses and one with a partial response). The five ALK-FISH-'borderline'-positive and IHC-negative patients all received crizotinib treatment. Two had a complete response, one a partial response and two progressed. Interestingly, the three responding patients showed high c-MET expression, while the two patients with ALK-'borderline' positivity but c-MET negativity progressed. We were not able to draw any statistical conclusions about the association of high c-MET expression and the crizotinib response in this small population. The two patients with discordant FISH-negative and IHC-positive tumors were not treated with crizotinib based on the ALK negativity obtained by FISH.
discussion
To date the FISH assay using the Vysis break-apart probe set (Abbott) is the only companion diagnostic for crizotinib licensed by the FDA [10] . In this study, the rate of ALK FISHpositive lung adenocarcinomas cases with double-negative EGFR and KRAS wild-type was 15%, which is consistent with previous data reported in Caucasian patients [2, 19] . The higher proportion of ALK-rearranged cells in tumors with a single red pattern of positivity compared with the percentage of ALK-positive cells in tumors with a break-apart pattern suggests that split and fused patterns may be challenging to distinguish, as recently reported [8] (supplementary Material, available at Annals of Oncology online). Regardless of technical and logistical issues, this method does not have 100% sensitivity and specificity by itself and demonstrates cellular false-negative and false-positive cases [21, 22] . In addition to the break-apart FISH assay, other ALK diagnostic techniques have been developed, including the use of IHC (supplementary Material, available at Annals of Oncology online). In the present study, a considerable proportion of 19% of cases were identified as ALK rearranged with a BA pattern by FISH in the 15% to 20% range. All cases were identified as negative by IHC and RT-PCR. The lack of EML4-ALK fusion transcripts may explain the absence of the ALK protein in FISH-'borderline'-positive cases [23] . We cannot exclude that rare ALK fusion transcripts other than EML4 may cause ALK positivity by FISH, although such translocations appear to be diffusely expressed in a large number of tumor cells [24] . Additionally, no high ALK copy number was observed in these tumors (supplementary Material, available at Annals of Oncology online). Furthermore, we identified three of five discordant cases overexpressing c-MET. It has been previously suggested that response to crizotinib, an inhibitor with activity to ALK as well c-MET and ROS1, may determine which type of testing is the most relevant in predicting the response to ALK inhibition [22] . Although only preliminary data were available from our study, it was interesting to observe that patients with ALK FISH 'borderline' rearrangements and high c-MET tumor expression responded to treatment. The two patients identified as ALK FISH-'borderline' positive, but negative for ALK, c-MET or ROS1 protein expression by IHC progressed after treatment with crizotinib. Recent reports showed that c-MET tumor overexpression is significantly increased in ALK-rearranged NSCLC [25] . Although, the therapeutic significance of high c-MET expression in ALKrearranged NSCLC patients is currently unknown, major responses to crizotinib were demonstrated in NSCLC patients with de novo c-MET amplification in the absence of ALK rearrangement [4, 5] .
While IHC-positive cases displayed homogeneous strong staining, we also demonstrated two cases with heterogeneous staining identified as positive for ALK expression. The FISH analysis revealed ALK rearrangements in <15% of tumor cells (analysis of at least 100 tumor cells) but demonstrated instead a high native ALK copy number. Alterations in the ALK copy number have recently been described in NSCLC [26, 27] . Along with ALK point mutations, ALK gene amplification may lead to ALK expression in the absence of ALK rearrangements and can possibly explain the discordant FISH-negative NSCLC cases [28] . Considering that crizotinib inhibits the ALK protein and not specifically ALK rearrangements, it is tempting to speculate that NSCLCs with ALK expression potentially caused by a high ALK copy number but without ALK rearrangements are also dependent on ALK signaling pathways, and may respond to crizotinib. However, this has not been proven yet, and further clinical studies are warranted. In our study, the two patients with discordant FISH-negative and IHC-positive tumors were not treated with crizotinib based on the analysis by FISH. To date, it is unclear whether the ALK copy number status could be predictive of either sensitivity or resistance to crizotinib [17, 29] . Recent studies noted response to crizotinib among patients who had tumors with discordant results (either FISH-positive and IHC-negative or FISH-negative and IHC-positive) [16, 30] . However, the native ALK copy number status was not evaluated in these studies. Moreover, while some in vitro studies reported an association between the ALK copy number and crizotinib sensitivity in NSCLC cell lines, amplification of the ALK fusion gene may constitute a mechanism of resistance to crizotinib in NSCLC patients [17, 22, 28] .
Finally, besides the biological insight revealed by discrepancies in the ALK status between the FISH and IHC in our study, some technical considerations should be discussed supplementary Material, available at Annals of Oncology online). Several ALK antibodies are currently available. The two clones 5A4 and D5F3 were reported to be high-affinity antibodies [12, 21] . Recently, the accuracy of a fully automated and standardized ALK IHC assay using the D5F3 antibody (Ventana) was examined in several studies and was shown to correlate with the FISH results [9, 14, 21] (supplementary Material, available at Annals of Oncology online). The standardization of the interpretation of ALK staining has been recently validated by an international team of expert pathologists [14] .
In our study, based on the current recommendations for ALK positivity by FISH, the IHC D5F3 assay demonstrated a sensitivity of 81%, and a specificity of 99%. Based on the biological observations in this study, an increase in the cutoff point to ≥20% ALK-rearranged cells identified by FISH would generate 100% sensitivity and 99% specificity for the IHC assay. To fully understand discrepancies between IHC compared with FISH in predicting response and outcome to ALK inhibitors, further evaluation of several biological features such as the variation of the native ALK copy number as well as the c-MET and ROS1 protein expression is needed. This would have some important practical implications (e.g. ease of FISH interpretation) as well as biological inferences (variation in the native ALK copy number in heterogeneous IHC stained cases).
In conclusion, this work highlights that given the biological features of the discordant cases between IHC and FISH it should be possible to minimize missed therapeutic opportunities among the true crizotinib-sensitive population by assessing the status of ALK rearrangements and alterations in the copy number along with ALK, c-MET and ROS1 protein expression in patients with advanced lung adenocarcinoma. disclosure
